Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support services; Warehousing, including dedicated storage, shared warehouses, packing and value-added services, such as labeling and products assembly; Logistics systems, including software for logistics management; Passenger transportation, including transportation of personnel and students; Special services, including rental of bus and vans; Moving, including national and international moving services, and Advertising, including custom transportation services during marketing campaigns. The Company operates through a number of group companies.

PINL:GRPOF - Post by User

Traxion Sab De Cv Ord Shs > video interview

<< Previous

Bullboard Posts

Next >>

Comment by MiningGospelon Apr 24, 2021 1:21am

215 Views

Post# 33060813

RE:RE:RE:RE:RE:RE:video interview

This is completely incorrect. There is a pharmaceutical standard to achieve. Contaminants are a huge deal with pressed flower and TBP has dealt with this already. And insurance providers would cover the cost of the drug so no, your scenario is highly unethical and improbable

lscfa wrote:
The co. is spending millions to prove that inhaled cannabis is better than opioids. If successful why would doctors prescribe QIXLEEF, especially if it is priced a lot higher than other medical cannabis? There's a risk doctors will piggyback off the QIXLEEF study and write their patients a note for some other medical cannabis with a similar THC:CBD ratio.

lscfa wrote:

Synthetic thc/CBD is still the way to go.

Nov 25, 2019 - QIXLEEF is the company’s first-generation cannabinoid therapeutic in development for treating advanced cancer patients with uncontrolled pain. The company believes a subset of the advanced cancer patient population prefers to consume cannabis in the traditional way, using dried flower bud as a drug product. In early 2019, Tetra uncovered an impurity in the dried flower bud cannabis and worked diligently to find solutions to develop a pharmaceutical grade cannabis drug free of any traces of the impurity.

MiningGospel wrote: There's something called the Entourage effect, where CBD +THC + Terpenes work in conjunction with each other to help with pain relief. Rafi Mechoulum has done a lot of work in this field

lscfa wrote:
More confusion:

CAUMZ is a synthetic drug and QIXLEEF is a plant-based drug. Why?

QIXLEEF has a fixed ratio of cbd:thc. What is CAUMZ mimicking as a synthetic?

Why not make QIXLEEF synthetically to ensure a fixed ratio? Can a grower (Aphria) really guarantee consistency with tight tolerances?

lscfa wrote: Interviewer asked what is it that investors are not getting? Part of the answer is confusion on whether Tetra is a cannabis stock or a biotech stock. I would add there is confusion on what is difference between CAUMZ and QIXLEEF. Are they both synthetic cannabis drugs? If so, why is Aphria the manufacturer? Does Aphria make synthetic cannabinoids?